Clinical Study of Low Molecular Weight Heparin Calcium Combined with Clopidogrel in the Treatment of Progressive Ischemic Stroke

Abstract

To investigate the efficacy of low molecular weight heparin calcium combined with clopidogrel in treating progressive ischemic stroke is the objective of the study. 150 patients of progressive ischemic stroke in 3201 hospital were divided into observation group and control group, 75 patients in each group. In addition to conventional therapy, the control group was treated with low molecular weight heparin calcium while the observation group was treated with low molecular weight heparin calcium and clopidogrel. The efficacy of the two groups after drug treatment, National institutes of health stroke scale score, neuropathy disability score and serum C-reactive protein level before treatment, and 7 d and 14 d after treatment was compared and analyzed. The effective rate of observation group was 86.7 % and the control group was 76.0 %. Serum C-reactive protein levels were compared between the two groups before treatment (p>0.05). The C-reactive protein values were decreased in both groups, but the C-reactive protein values in observation group and 7 d and 14 d after treatment were reduced more obviously than control group (all, p<0.05). Low molecular weight heparin combined with clopidogrel can effectively treat progressive ischemic stroke and improve the neurological function of progressive ischemic stroke patients, which is worth of clinical application.